1. Home
  2. TVRD vs TDAC Comparison

TVRD vs TDAC Comparison

Compare TVRD & TDAC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • TVRD
  • TDAC
  • Stock Information
  • Founded
  • TVRD 2017
  • TDAC 2022
  • Country
  • TVRD United States
  • TDAC United States
  • Employees
  • TVRD N/A
  • TDAC N/A
  • Industry
  • TVRD Biotechnology: Pharmaceutical Preparations
  • TDAC
  • Sector
  • TVRD Health Care
  • TDAC
  • Exchange
  • TVRD Nasdaq
  • TDAC NYSE
  • Market Cap
  • TVRD 246.5M
  • TDAC 221.0M
  • IPO Year
  • TVRD N/A
  • TDAC 2024
  • Fundamental
  • Price
  • TVRD $28.34
  • TDAC $10.19
  • Analyst Decision
  • TVRD Strong Buy
  • TDAC
  • Analyst Count
  • TVRD 2
  • TDAC 0
  • Target Price
  • TVRD $52.00
  • TDAC N/A
  • AVG Volume (30 Days)
  • TVRD 48.4K
  • TDAC 1.9K
  • Earning Date
  • TVRD 05-13-2025
  • TDAC 01-01-0001
  • Dividend Yield
  • TVRD N/A
  • TDAC N/A
  • EPS Growth
  • TVRD N/A
  • TDAC N/A
  • EPS
  • TVRD N/A
  • TDAC 0.16
  • Revenue
  • TVRD N/A
  • TDAC N/A
  • Revenue This Year
  • TVRD N/A
  • TDAC N/A
  • Revenue Next Year
  • TVRD N/A
  • TDAC N/A
  • P/E Ratio
  • TVRD N/A
  • TDAC $160.63
  • Revenue Growth
  • TVRD N/A
  • TDAC N/A
  • 52 Week Low
  • TVRD $8.13
  • TDAC $10.00
  • 52 Week High
  • TVRD $34.31
  • TDAC $10.24
  • Technical
  • Relative Strength Index (RSI)
  • TVRD N/A
  • TDAC N/A
  • Support Level
  • TVRD N/A
  • TDAC N/A
  • Resistance Level
  • TVRD N/A
  • TDAC N/A
  • Average True Range (ATR)
  • TVRD 0.00
  • TDAC 0.00
  • MACD
  • TVRD 0.00
  • TDAC 0.00
  • Stochastic Oscillator
  • TVRD 0.00
  • TDAC 0.00

About TVRD Tvardi Therapeutics Inc. Common Stock

Tvardi Therapeutics Inc is a clinical-stage biopharmaceutical company focused on the development of novel, oral small molecule therapies targeting STAT3 to treat fibrosis-driven diseases. Its key product candidate, TTI-101, is in Phase 2 clinical development for the treatment of idiopathic pulmonary fibrosis (IPF), and hepatocellular carcinoma (HCC). Its second product candidate, TTI-109, is structurally related to, yet chemically distinct from, TTI-101 and is designed to enhance the ability to target STAT3.

About TDAC TRANSLATIONAL DEVELOPMENT ACQUISITI

Translational Development Acquisition Corp is a newly organized blank check company.

Share on Social Networks: